Video Library

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Kessler, from the University of Coloradeo Cancer Center. For more information on Dr. Kessler, please visit her bio here. In part one of

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses First Line EGFR-Based Therapy For Advanced Squamous Non-Small Cell Lung Cancer (NSCLC).

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University joined GRACE to discuss EGFR mutation: what is it, and which patients have it?

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University joined GRACE to discuss different types of EGFR mutations and their potential clinical implications.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses current standards and options for first-line treatment of EGFR mutation-positive NSCLC.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses treatment options for acquired resistance to EGFR TKIs: T790M-positive disease.

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses the changing landscape of first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC).

Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses liquid biopsies for EGFR T790 non-small cell lung cancer (NSCLC). We would like to thank the following companies for their support of this program

For our Mandarin speaking community, Jenny J. Li, MD, Hematology/Oncology Fellow at the Mayo Clinic in Rochester MN, offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Li discusses evolving standards for molecular testing in advanced NSCLC. We would like to

We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community. Translating Molecular Oncology Results into Targeted Therapy Treatment For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Luis E. Raez

We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community. Para conocer las adiciones más recientes a nuestra Biblioteca de videos sobre cáncer de pulmón, producida en español para nuestra comunidad latina, el Dr. Luis E. Raez nos brinda la

We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom furthers his discussion with Dr. Elizabeth Kessler, from the University of Colorado Cancer Center. For more information on Dr. Kessler, please visit her bio here. In

We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Petros Grivas, from the University of Washington and the Fred Hutchinson Cancer Center. For more information on Dr. Grivas, please visit his bio